Oral Anticoagulants come with risk factors for many NVAF patients—including adherence issues and bleeding risks that compound over time.

Example of Risk Factors and Limitations of Blood Thinners

  • Bleeding risk
  • Daily regimen
  • High non-adherence rates
  • Regular INR monitoring
  • Food and drug interaction issues
  • Complicates surgical procedures
  • Limited reversal agents
  • High cost


The WATCHMAN Advantage

Proven Stroke Risk Reduction. Freedom From Blood Thinners.

With over 10 clinical studies and 70k+ patients implanted, WATCHMAN is an effective and safe way for your NVAF patients to avoid the challenges that can come with blood thinners.

55% lower relative risk of disabling or fatal strokes vs. warfarin after 5 years1

72% reduction in major bleeding events vs. warfarin more than 6 months post procedure2

95% implant success rate4 with a low 1.5% complication rate5—similar to ablation therapy


The Implant Procedure

See how WATCHMAN provides protection from stroke for your NVAF patients, starting with the one-time, minimally invasive implant procedure.



Consider WATCHMAN for Your NVAF Patients

WATCHMAN may be right for many of your NVAF patients in need of an alternative to OACs, including those with:

  • A history of bleeding
  • Risk of future bleeds
  • Compliance issues
  • Lifestyle or occupation issues
  • Drug interaction issues


Learn more about the WATCHMAN Indication

Referring Your Patients for WATCHMAN

Referring your NVAF patients for WATCHMAN is a simple 3-step process:

Give your patients the information they need, including our patient education resources and the implanting physician’s contact information.

Using a referral form or EMR (depending on the implanting physician’s preferred method), document your consultation so the implanting physician has access to all referral information.

Send the referral form to an implanting physician via their preferred referral method. Looking for a local implanting physician? Find one here >

1. Reddy VY, et al. JACC 2017; 70(24): 2964–2975. 

2. Price, MJ, et al. JACC: CV Interv 2015; 8(15): 1925–1932. 
PREVAIL findings (3 Years vs. 5)

*4. Holmes DR Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64(1):1–12. 
*Procedural Success defined as deployment and release of the device into the LAA with no leak greater than or equal to 5mm

5. Varosy P et al. JACC 2018; 71(11): A320.